Heart disease kills 18 million people each year, but the development of new therapies faces a bottleneck: no physiological model of the entire human heart exists – so far. A new multi-chamber organoid ...

The researchers say the technology could eventually support more personalised care, allowing treatments to be better matched ...

A study led by Maria Carmo-Fonseca at GIMM has helped clarify one of the main limitations of lab-grown heart cells, which are ...

An advanced human heart organoid system can be used to model embryonic heart development under pregestational diabetes-like conditions, researchers report. The organoids recapitulate hallmarks of ...

Having explored how the heart is formed in utero, a University of Houston pharmacology researcher is reporting how cells and molecules act during that early formation and what might cause the heart ...

Cardiovascular diseases (CVDs) remain the leading cause of death worldwide. Several risk factors, including genetics, sex, and age, increase the risk of CVDs. Other factors that contribute to CVD ...

New ACC/AHA guidelines update management of adults with congenital heart defects but highlight the shortage of specialists ...

Share on Pinterest Research shows that poor heart health may put people at risk of multiple musculoskeletal disorders. Ronald Martinez/Getty Images Researchers investigated the link between ...

Heart disease kills 18 million people each year, but the development of new therapies faces a bottleneck: no physiological model of the entire human heart exists – so far. A new multi-chamber organoid ...

Tenaya Therapeutics (TNYA) is a very interesting biotech because it is in the process of developing two one-time gene therapies to treat patients with common genetic heart disorders. I believe that ...